David A. Kennard
Corporate Officer/Principal en Royal Pharmaceutical Society of Great Britain .
Perfil
David A.
Kennard is a Member of the Royal Pharmaceutical Society of Great Britain.
He was previously the Chief Executive Officer & Director of NeuroTargets Ltd.
and the Chief Operating Officer of Silence Therapeutics Plc.
He also served as the Director-European Operations at YM BioSciences, Inc. Kennard holds an MBA and a doctorate from the University of London.
Cargos activos de David A. Kennard
| Empresas | Cargo | Inicio |
|---|---|---|
Royal Pharmaceutical Society of Great Britain
 Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Corporate Officer/Principal | - |
Antiguos cargos conocidos de David A. Kennard.
| Empresas | Cargo | Fin |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Director de Operaciones | - |
NeuroTargets Ltd.
 NeuroTargets Ltd. Pharmaceuticals: MajorHealth Technology NeuroTargets, Inc. develops novel therapeutic products. It discovers and develops new drugs for neurological diseases. The company develops products in the fields of diabetic neuropathy, pain resulting from nerve damage, spinal cord injuries and other trauma, and brain diseases associated with cognitive impairment such as stroke and Alzheimer's disease. NeuroTargets was founded in 1999 and is located at Guildford, UK. | Presidente | - |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - |
Formación de David A. Kennard.
| University of London | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Empresas privadas | 3 |
|---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Royal Pharmaceutical Society of Great Britain
Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Commercial Services |
NeuroTargets Ltd.
NeuroTargets Ltd. Pharmaceuticals: MajorHealth Technology NeuroTargets, Inc. develops novel therapeutic products. It discovers and develops new drugs for neurological diseases. The company develops products in the fields of diabetic neuropathy, pain resulting from nerve damage, spinal cord injuries and other trauma, and brain diseases associated with cognitive impairment such as stroke and Alzheimer's disease. NeuroTargets was founded in 1999 and is located at Guildford, UK. | Health Technology |
- Bolsa de valores
- Insiders
- David A. Kennard